Small cell lung cancer (SCLC), which represents 20%
|
|
- Beryl Ray
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD, Keiji Iuchi, MD, Hajime Maeda, MD, and Hikaru Matsuda, MD, for the Thoracic Surgery Study Group of Osaka University, Osaka, Japan Department of Surgery, Osaka Prefectural Habikino Hospital, Department of Surgery, Course of Interventional Medicine (E1), Osaka University Graduate School of Medicine, Department of Surgery, National Kinki Central Hospital for Chest Diseases, and Department of Surgery, Toneyama National Hospital, Osaka, Japan Background. Operation with combined chemotherapy has been recently recommended for very early stage of small cell lung cancer without lymph node metastasis. Methods. A retrospective study was undertaken in 91 patients who had undergone pulmonary resection for small cell lung cancer according to the new international staging system. Results. The 5-year overall probability of survival was 37.1%. The 5-year survival rate was 100% for p-stage 0, 56.1% for p-stage IA, 30.0% for p-stage IB, 57.1% for p-stage IIA, and 42.9% for p-stage IIB. In the p-stage IA IIB patients who underwent a complete resection, the 5-year survival rate of the patients treated by operation with chemotherapy was better than that of patients treated by operation alone. In addition, the 5-year survival rate of the patients who had four or more courses of chemotherapy was 80.0%. Conclusions. These results suggest that operation should be considered for p-stage IA IIB patients and more than four courses of combined chemotherapy might be desirable in these resectable cases. (Ann Thorac Surg 2000;70:1615 9) 2000 by The Society of Thoracic Surgeons Small cell lung cancer (SCLC), which represents 20% to 25% of all lung cancer cases, shows a high grade malignancy with a rapid growth and early metastasis to other organs as compared with non-small cell lung cancer [1]. As for the treatment for SCLC, operation was once abandoned after the results reported by the British Medical Research Council and chemotherapy has played a great role [2]. Chemotherapy has been generally accepted as effective for SCLC and the response rate has been reported to be 80% to 90%. However, local recur- For editorial comment, see page rence has been frequently found even in those patients who show complete remission and the 5-year survival has been reported as 19% to 23% in limited disease (LD) [3 5]. Recently, a surgical treatment with combined chemotherapy has been recommended in LD patients without lymph node metastasis [6 11]. In this study, we retrospectively analyzed SCLC patients who had undergone pulmonary resection according to the new TNM staging system to clarify the operative indication and significance of the chemotherapy treatment in these resectable cases [12]. Accepted for publication Jan 5, Address reprint requests to Dr Miyoshi, Department of Surgery, Course of Interventional Medicine (E1), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka , Japan; miyoshi@surg1.med.osaka-u.ac.jp. Material and Methods Between January 1975 and December 1994, thoracotomies were performed in 3,497 lung cancer patients at Osaka University Hospital, Osaka Prefectural Habikino Hospital, National Kinki Central Hospital, and Toneyama National Hospital. Among them, there were 95 SCLC patients (2.7%) including four exploratory thoracotomies. Ninety-one SCLC patients treated by pulmonary resection were enrolled in this study. The patient characteristics are shown in Table 1. A histologic or cytologic diagnosis was performed using the specimens obtained by a transbronchial lung biopsy or percutaneous needle biopsy. Sixty-one patients were diagnosed as SCLC, 8 as squamous cell carcinoma, 5 as adenocarcinoma, whereas 17 could not be diagnosed preoperatively. Clinical staging was evaluated using a computed tomography of the chest, brain, and abdomen, as well as bone scintigraphy. There were 32 patients with c-stage IA, 30 with c-stage IB, 6 with c-stage IIA, 12 with c-stage IIB, and 11 with c-stage IIIA. An operative indication was considered for c-stage IA IIB in patients who had been preoperatively diagnosed as SCLC. The operative cases with c-n2 included 8 patients who had not been confirmed as SCLC preoperatively, and 1 patient who had been reduced to y-n0 by induction chemotherapy. Pathologically, there were 4 patients with p-stage 0, 30 with p-stage IA, 20 with p-stage IB, 7 with p-stage IIA, 7 with p-stage IIB, 19 with p-stage IIIA, and 4 with p-stage IIIB. A pneumonectomy was performed in 10 patients, lobectomy in 77 patients, and segmentectomy or 2000 by The Society of Thoracic Surgeons /00/$20.00 Published by Elsevier Science Inc PII S (00)
2 1616 INOUE ET AL Ann Thorac Surg OPERATION FOR SMALL CELL LUNG CANCER 2000;70: Table 1. Characteristics of SCLC Patients Treated by Pulmonary Resection Characteristics Data Age (yr) ( ) Sex male 75, female 16 Preoperative diagnosis SCLC 61, SQ 8, AD 5, not determined 17 c-stage IA 32, IB 30, IIA 6, IIB 12, IIIA 11 (T3N1 2, T1-2N2 7, T3N2 2) p-stage 0 4, IA 30, IB 20, IIA 7, IIB 7, IIIA 19 (T1-2N2 14, T3N2 5), IIIB 4 (T4N1 2, T4N2 1, T2N3 1) Operation Pneumonectomy 10, lobectomy 77, segmentectomy or partial resection 4 Chemotherapy 71 (pre- and postoperative 9, preoperative 20, postoperative 42) Radiation therapy 17 (PCI 5) AD adenocarcinoma; PCI prophylactic cranial irradiation; SQ squamous cell carcinoma. Table 3. Relationship Between c-n and p-n in SCLC Patients Who Did Not Receive Preoperative Chemotherapy p-n0 p-n1 p-n2 p-n3 Total c-n c-n c-n Total partial resection in 4 patients. As for the radicality, a curative resection was performed in 81 patients. Chemotherapy was performed in 71 patients, whereas 17 were irradiated, including 5 who had prophylactic cranial irradiation. Preoperative chemotherapy has been given to the good risk patients with histologic diagnosis of SCLC under the judgment of the attending physicians. The survival period was counted from either the operative date or the beginning date of induction chemotherapy. The mean follow-up period was months and the median was 136 months. Survival was estimated according to the method of Kaplan and Meier. The influence of variables on survival was analyzed using a log-rank test. The relative importance of various prognostic factors for postoperative survival as identified by multivariate analysis was performed with Cox s proportional hazards model with the forward stepwise method. Statistical analyses were performed with the commercially available personal computer program SPSS (SPSS Inc, Chicago, IL). A probability value of less than 0.05 was considered significant. Results Preoperative Evaluation We first compared the clinical stage with the pathologic stage in 62 patients who had not been treated by induction chemotherapy (Table 2). The accuracy was 61.3% (38 of 62 patients). We had underestimated the stage in 20 patients (32.3%). It was conspicuous that 6 patients had been underestimated out of 9 in c-stage IIB. On the other hand, we had overestimated the stage in only 4 patients (6.5%). As for the N-factor, the relationship between c-n and p-n is shown in Table 3. The accuracy by thoracic computed tomography was 67.7% (42 of 62 patients). We had underestimated the N-factor in 19 patients (30.6%), in which 6 were conspicuously included among the 10 c-n1 patients. We had overestimated only 1 patient (1.6%). Thus, our clinical stage underestimating was mainly due to the N-factor. Survival Rate by c-stage and p-stage The overall survival curve is shown in Figure 1. The 5-year probability of survival was 37.1% and the median survival time (MST) was 26 months. Figure 2 shows the survival curves by c-stage. The 5-year survival rate and MST were 49.4% and 53 months for c-stage IA, 46.7% and 25 months for c-stage IB, and 33.3% and 18 months for Table 2. Relationship Between c-stage and p-stage in SCLC Patients Who Did Not Receive Preoperative Chemotherapy p-stage IA IB IIA IIB IIIA IIIB Total c-stage IA IB IIA IIB IIIA Total Fig 1. Overall survival of small cell lung cancer patients who underwent pulmonary resection.
3 Ann Thorac Surg INOUE ET AL 2000;70: OPERATION FOR SMALL CELL LUNG CANCER 1617 Fig 2. Survival curves according to clinical stage. c-stage IIA, respectively. The MST was 14 months for c-stage IIB and 9 months for c-stage IIIA. The survival by p-stage is shown in Figure 3. The 5-year survival rate and MST were 56.1% and 67 months for p-stage IA, 30.0% and 23 months for p-stage IB, 57.1% and 106 months for p-stage IIA, and 42.9% and 14 months for p-stage IIB, respectively. The MST was 9 months for p-stage IIIA and 4 months for p-stage IIIB. Survival Rate by T-Factor and N-Factor We also analyzed the survival rate by pathologic T- and N-factor. As shown in Figure 4A, survival seemed to be determined by the T-factor and the 5-year survival rate was 100% for p-t0, 50.9% for p-t1, and 24.3% for p-t2. The survival rate for p-t1 patients was significantly better than that for p-t2 ( p ) and p-t2 was better than that for p-t3 ( p ). As for the p-n factor, the 5-year survival rate was 48.5% for p-n0 and 46.7% for p-n1 (Fig 4B). The survival rate for both p-n0 and p-n1 was significantly better than that of p-n2 ( p and p ). Fig 3. Survival curves according to pathologic stage. Chemotherapy for p-stage IA IIB Patients In the p-stage IA IIB patients who had undergone a complete resection, the survival rate for the 40 patients treated by operation and perioperative chemotherapy (preoperative 9, postoperative 27, both 4) was compared with that for the 9 patients treated by operation alone. The patients who received irradiation were excluded. As to chemotherapy regimens, vincristine (1.5 to 2.0 mg/ body) and cyclophosphamaide (600 to 1000 mg/m 2 ) had been mainly administered until Cisplatin (60 to 100 mg/m 2 ) and etoposide (240 to 360 mg/m 2 ) have been adopted at our facilities since As shown in Figure 5A, the 5-year probability of survival for patients with perioperative chemotherapy was 54.9%, as compared with 22.2% for patients without chemotherapy ( p , significant). However, there were several patients who did not have chemotherapy because of such complications such as heart disease, renal dysfunction, or liver dysfunction. Among those patients who had operation alone, 4 died of causes other than SCLC. When not considering patients whose cause of death was other than SCLC, a significant difference cannot be found in the 5-year probability of survival between patients with perioperative chemotherapy and those without chemotherapy. The 5-year survival rate for patients with four or more courses was 80.0%, as compared with 46.4% for patients treated with one to three courses ( p ; Fig 5B). By multivariate analysis with Cox s proportional hazards model, treatment with four or more courses of chemotherapy was shown to be an independent factor to determine postoperative survival. The p value and the relative risk were and , respectively. Survival did not depend on the T ( p ) or N (p ) factor. Comment The benefit of chemotherapy with irradiation for SCLC has been generally accepted. Five-year survival rate has been improved and reported as more than 20%, when chemoradiation therapy is given to LD patients [5]. On the other hand, operation has been recently adopted as a locoregional therapy in a combined modality therapy for SCLC [13]. As for the results of treatment with operation for LD, Shepherd and colleagues [7] reported that the 5-year survival rate was 51% for p-stage I, 28% for p-stage II, and 19% for p-stage IIIA. Karrer and Ulsperger [11] reported that the 4-year probability of survival was 56% for p-stage I and 29% for p-stage II, and Macchiarini and associates [8] reported a 5-year survival rate of 36% for p-n0 patients. For patients with T3 or N2 tumors, operation appears to offer little benefit other than as a salvage procedure [14]. Because it has been recommended to consider the value of the new TNM staging system for locoregional SCLC, we retrospectively reviewed the surgical results of 91 patients according to this new staging system [15]. According to the results in this study, we propose that operation should be indicated for c-stage
4 1618 INOUE ET AL Ann Thorac Surg OPERATION FOR SMALL CELL LUNG CANCER 2000;70: Fig 4. Survival curves by pathologic T-factor (A) and N-factor (B). p-t1 versus p-t2, p ; p-t2 versus p-t3, p p-n0 versus p-n2, p ; p-n1 versus p-n2, p IA IIA and p-stage IA IIB with accurate preoperative staging. Because the results of chemoradiation therapy for the very early LD (ie, stage I II) patients had not been clarified yet, at present we cannot compare the results of chemoradiation with those of operation. Clinical staging for lung cancer has become precise with an improvement in diagnostic imaging [16 18]. It was, however, reported that a lymph node metastasis is often underestimated in SCLC patients. Shepherd and colleagues [7] reported that 58 c-stage I patients included only 28 at p-stage I and most of the remaining 30 cases had been underestimated due to false-negative results concerning lymph node metastasis. In our study, although c-n0 comparatively corresponded with p-n0, c-n1 patients included 60% with p-n2 disease. A diagnosis of c-n1 may suggest the possibility of p-n2. Therefore, a mediastinal exploration using either mediastinoscopy or mediastinotomy, or both, is mandatory to rule out occult mediastinal lymph node metastasis as Shields and associates [14] suggested. However, it was pointed out that occult mediastinal involvement might be missed even by medistinoscopy in SCLC [7]. Fluoro-2-deoxy-Dglucose Positron Emission Tomography (FDG-PEG) may be useful for the evaluation of mediastinal lymph nodes [16, 17]. How N2 disease could be accurately diagnosed before a thoracotomy is still an important issue to be solved. Operation will be indicated for the patients with c-stage IIB if more accurate evaluation is possible. An analysis by the new TNM staging system revealed that the survival rate in p-stage IB was worse than that in p-stage IIA, although the number of patients was small. A detailed analysis interestingly showed that the T- factor, rather than the N-factor, determined the prognosis in these resectable cases. Shields and colleagues [14] also reported that large lesions more than 3 cm (T2), even without lymph node metastasis (N0), have a less favor- Fig 5. (A) Survival curves for p-stage IA IIB patients who underwent complete resection with or without adjuvant chemotherapy. (B) Survival curves for p-stage IA IIB patients who underwent complete resection with four or more chemotherapy courses versus one to three courses.
5 Ann Thorac Surg INOUE ET AL 2000;70: OPERATION FOR SMALL CELL LUNG CANCER 1619 able prognosis than either of the aforementioned categories (T1N0M0 or T1N1M0). On the contrary, Angeletti and associates [18] reported that the N-factor has a stronger negative effect on prognosis than the T factor. These contradictions may depend on a difference in patient population or perioperative chemotherapy. It is possible that perioperative chemotherapy improves the survival in p-stage IA IIB patients who undergo curative resection, as SCLC shows a high response rate for chemotherapy. Actually, the multivariate analysis demonstrated that four or more courses of chemotherapy is only one independent factor to determine the postoperative survival of the IA IIB patients. The patients in this study received 2.3 courses of chemotherapy on average, which seems to be insufficient. According to the results in this study, we suppose that four or more courses of perioperative chemotherapy are recommended, even for resectable patients with p-stage IA IIB, although it cannot be denied that the good risk patients who were unable to receive four or more courses of chemotherapy show the favorable prognosis [7, 8, 10, 11]. There is no significant difference in survival among the patients with preoperative chemotherapy, those with postoperative chemotherapy, and those with both in our study. As for the regimen, cisplatin and etoposide were administered in 8 of the 10 patients treated with four or more courses of chemotherapy. Thus, at present we can reconfirm the adequacy of this chemotherapy regimen, while the development of new carcinostatics is expected. Further prospective study is required to determine the regimen and timing of chemotherapy. As for postoperative irradiation, local recurrence was found in 4 patients among 12 treated by thoracic radiation. Brain metastasis was found in 1 patient among the 5 treated with prophylactic cranial irradiation. A distinct survival benefit could not be found in this study. Thus, complete control of SCLC by adjuvant radiation therapy could not be expected, although the progress of the disease was not the target of this study. It was previously reported that salvage operation might be considered for c-stage IIIA cases who remarkably respond to chemotherapy or local recurrent cases after chemotherapy [19, 20]. In our study, a c-stage IIIA patient underwent an operation after being restaged to y-stage IA by curative chemotherapy and survived for 38 months. This patient was initially considered as inoperable due to the metastatic mediastinal node. Any operative indication for c-stage IIIA patient who has good response to chemotherapy should be considered. In summary, a retrospective analysis of surgical results for SCLC based on the new TNM staging system suggested that operation should be indicated for c-stage IA IIA and p-stage IA IIB patients who have had four or more courses of perioperative chemotherapy. In this situation, an accurate preoperative diagnosis of the N- status is required. References 1. Ihde DC. Current status of therapy for small cell carcinoma of the lung. Cancer 1984;54: Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: ten-year follow-up. Lancet 1973;2: Wiatr E, Starzynska T, Danczak-Ginalska Z, Zych J, Rowinska-Zakrzewska E. Survival of patients with limited small cell lung cancer in whom complete remission was obtained (a non-randomised retrospective study of 124 consecutive patients). Lung Cancer 1995;13: Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996;14: Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340: Meyer JA. Five-year survival in treated stage I and II small cell carcinoma of the lung. Ann Thorac Surg 1986;42: Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small-cell lung cancer. J Thorac Cardiovasc Surg 1991;101: Macchiarini P, Hardin M, Basolo F, Bruno J, Chella A, Angeletti CA. Surgery plus adjuvant chemotherapy for T1-3N0M0 small-cell lung cancer. Am J Clin Oncol 1991;14: Hara N, Ohta M, Ichinose Y, et al. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 1991;47: Coolen L, Van den Eeckhout A, Deneffe G, Demedts M, Vansteenkiste J. Surgical treatment of small cell lung cancer. Eur J Cardiothorac Surg 1995;9: Karrer K, Ulsperger E. Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. Acta Oncol 1995;34: Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111: Deslauriers J. Surgery for small cell lung cancer. Lung Cancer 1997;17(Suppl 1):S Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982;84: Ginsberg R, Cox J, Green M, et al. Staging classification committee. Lung Cancer 1997;17(Suppl 1):S Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16: Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202: Angeletti CA, Macchiarini P, Mussi A, Basalo F. Influence of T and N stages on long-term survival in resectable small cell lung cancer. Eur J Surg Oncol 1989;15: Shepherd FA, Ginsberg R, Patterson GA, et al. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg 1991;101: Zatopek NK, Holoye PY, Ellerbroek NA, et al. Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol 1991;14:
Although the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationA Pilot Phase 2 Study of Surgical Treatment After Induction Chemotherapy for Resectable Stage I to lila Small Cell Lung Cancer*
preliminary report A Pilot Phase 2 Study of Surgical Treatment After Induction Chemotherapy for Resectable Stage I to lila Small Cell Lung Cancer* Katsuya Fujimori, MD/ Akira Yokoyama, MD; Yuzo Kurita,
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationIntraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer
Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationSurgical intervention for small-cell lung cancer: what is the surgical role?
Gen Thorac Cardiovasc Surg (2012) 60:401 405 DOI 10.1007/s11748-012-0072-9 CURRENT TOPICS REVIEW ARTICLE Surgical intervention for small-cell lung cancer: what is the surgical role? Masayoshi Inoue Noriyoshi
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationEffect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma
ORIGINAL ARTICLE Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma Nader Abedallaa, MD,* Lise Tremblay, MD, Charlotte Baey,* Dominique Fabre, MD, David
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationSmall-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationSurgery for Early-Stage Small Cell Lung Cancer
1132 Surgery for Early-Stage Small Cell Lung Cancer Bryan J. Schneider, MD a ; Ashish Saxena, MD a ; and Robert J. Downey, MD b ; New York, New York Key Words Small cell lung cancer, surgery, resection,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationIs neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer?
Interactive CardioVascular and Thoracic Surgery Advance Access published August 24, 2014 Interactive CardioVascular and Thoracic Surgery (2014) 1 7 doi:10.1093/icvts/ivu262 THORACIC Is neoadjuvant chemotherapy
More informationRisk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationCytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer
Cytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer Noriyoshi Sawabata, MD, Akihide Matsumura, MD, Mitsunori Ohota, MD, Hajime Maeda, MD, Hiroshi Hirano, MD, Katsuhiro
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationWHITE PAPER - SRS for Non Small Cell Lung Cancer
WHITE PAPER - SRS for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationLung Cancer Update. HARMESH R NAIK, MD. February 28, 2001
Lung Cancer Update HARMESH R NAIK, MD. February 28, 2001 Progress update Prevention Screening Staging Treatment Epidemiology Estimated 169,500 new cases Estimated 157,400 deaths Second commonest cancer
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationVariability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival
Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationNon small cell lung cancer (NSCLC) with ipsilateral mediastinal
Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPostoperative survival of non small cell lung cancer
Biological Features and Preoperative Evaluation of Mediastinal Nodal Status in Non Small Cell Lung Cancer Fumihiro Tanaka, MD, Kazuhiro Yanagihara, MD, Yosuke Otake, MD, Mio Li, MD, Ryo Miyahara, MD, Hiromi
More informationDespite advances in radiation therapy, chemotherapy, Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer
Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M. Bhamidipati, DO, MS, Nicholas Theodosakis, BS, Benjamin D. Kozower,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationThe prognosis for patients with surgically resected
Prognostic Factors in Clinical Stage I Non Small Cell Lung Cancer Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Eiji Moriyama, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, and Yutaka Nishiwaki,
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More information